Tetratherix Targets First Regenerative Product Sales and Pivotal Trial in FY27
TTX: $6.40 +0.79% · MC: $340M
At its AGM, Tetratherix outlined FY27 plans to pursue US clearance for its bone regeneration products, followed by market seeding and first regenerative product sales. It also plans to enrol the first patients in Tutelix’s pivotal trial and is selecting a long-term partner for TegenEOS. The company said its manufacturing campus would lift capacity tenfold and that MDSAP certification was now in place, after reporting last month that certification was expected in the coming months.

Comments